EP4343000A1 - Dosage de libihrd (analyse rapide de hpv par biopsie liquide) - Google Patents
Dosage de libihrd (analyse rapide de hpv par biopsie liquide) Download PDFInfo
- Publication number
- EP4343000A1 EP4343000A1 EP22197523.8A EP22197523A EP4343000A1 EP 4343000 A1 EP4343000 A1 EP 4343000A1 EP 22197523 A EP22197523 A EP 22197523A EP 4343000 A1 EP4343000 A1 EP 4343000A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- cleavage
- hpv
- hpv16
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims description 36
- 238000003556 assay Methods 0.000 title description 11
- 238000011528 liquid biopsy Methods 0.000 title description 2
- 108020004414 DNA Proteins 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000007017 scission Effects 0.000 claims abstract description 28
- 210000001124 body fluid Anatomy 0.000 claims abstract description 23
- 239000010839 body fluid Substances 0.000 claims abstract description 23
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 19
- 238000010453 CRISPR/Cas method Methods 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 19
- 239000013615 primer Substances 0.000 description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 230000003321 amplification Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 208000009608 Papillomavirus Infections Diseases 0.000 description 10
- 108091027544 Subgenomic mRNA Proteins 0.000 description 10
- 238000005520 cutting process Methods 0.000 description 9
- 101150071673 E6 gene Proteins 0.000 description 8
- 101150013359 E7 gene Proteins 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 description 7
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 6
- 108700004991 Cas12a Proteins 0.000 description 5
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 5
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 5
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011901 isothermal amplification Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 201000006958 oropharynx cancer Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101150075239 L1 gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 241000722343 Human papillomavirus types Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 101000909800 Xenopus laevis Probable N-acetyltransferase camello Proteins 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- HPV Human papilloma viruses
- HPV types include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, referred to as high-risk (HR) HPC types.
- HR high-risk
- HPV-induced oropharyngeal squamous cell carcinoma remains increasing worldwide. Recent data from the U.S. now even show that the number of newly diagnosed OPSCC patients exceeds that of cervical carcinomas. HPV infections are often transmitted sexually or through other skin-to-skin contact.
- HR HPV-variants include for example personal contact or damaged skin parts, in particular for skin-to-skin infections, weakened immune system, Cannabis consumption, smoking. alcohol consumption or number of sexual partners, in particular for sexually transmitted virus infections. Nevertheless, other risk factors remain to be explored.
- HR HPV variants are of particular clinical relevance, with early prognosis and monitoring of progression and malignant transformation of the disease becoming particularly highly relevant for patients.
- an easy, fast and reliable alternative detection method to overcome the above mentioned limitations regarding efficient detection of clinically relevant HPV infections and HPV related carcinomas.
- the method relies on the combination of different methods, which are partially known.
- provided herein are methods for fast, reliable, cost-effective and easy-to-use tests for valid detection of HPV circulating nucleic acids as well as kits and their use for diagnosis and/or monitoring of HPV infections and/or cancer.
- HPV human papilloma virus
- kits comprising means for detection cleavage of E6 DNA and / or E7 DNA in a body bluid as stated above and use of the kit for the diagnosing and/or monitoring of cancer.
- HPV human papilloma virus
- the human papilloma virus is HPV16 or HPV18.
- HPV human papilloma virus
- HPV is a righ-risk HPV strain.
- HPV human papilloma virus
- HPV low-risk HPV strain.
- HPV human papilloma virus
- the body fluid is a nasopharyngeal swab.
- the body fluid is an oral swab.
- the body fluid is saliva.
- the body fluid is urine.
- the body fluid can be mucus.
- the body fluid is blood.
- the body fluid may, in principle, be derived from any animal, because the method disclosed herein is universally applicable.
- the body fluid is derived from a human subject.
- Amplification means the production of multiple copies of a sequence of DNA. Amplification, as defined above, can be performed by any method in the art. Thus, as an alternative to RPA as disclosed herein, the amplification of DNA can be performed by using polymerase chain reaction (PCR), as it is commonly known in the art for decades.
- PCR polymerase chain reaction
- RPA Recombinase Polymerase Amplification
- SSB single-stranded DNA binding
- RPA provides several advantages: First, RPA provides a very fast way of amplification as there is no need for modifying the temperature of the sample in order to produce amplification products. RPA works at optimum reaction temperatures at a broad spectrum of about 37-42°C. Moreover, RPA is highly sensitive and provides high specificity rates. RPA can detect single copies of DNA and tens of copies or fewer of RNA in complex samples, without the need for prior nucleic acid purification, providing additionally time saving. As RPA is performed isothermal, no need for melting of the DNA is needed, as it is commonly done within a PCR reaction. Thus, the reaction can be performed at room temperate, without any further complex machineries. Giving these advantages, RPA provides the first step of a fast, versatile and cheap determination method of the present invention. Of note, all RPA kits that are commercially available can be used in the context of the present invention.
- HPV-E6 and -E7 of HPVs at risk for developing carcinoma are both oncogenes, playing a major role in the establishment and the development of human HPV infections ( Scheffner et al., Cell, 1990 ).
- initial establishment and subsequent progression of OPSCC or cervix cancer are completely dependent on these two major oncogenes E6 and E7, which are expressed constitutively leading to tumorigenesis.
- Both proteins are encoded by oncogenic human papillomavirus types such as 16 and 18 and are mandatorily expressed in HPV-associated cancers.
- oncoproteins have pleiotropic functions, such as regulation of the cell cycle towards increased proliferation, inhibition of apoptosis, metabolic reprogramming towards anabolic reactions, upregulated telomerases and deregulated chromosomal stability. These functions are well established and can be used to transform established cell lines due to immortalization of primary cell lines. Thus, the viral E6 and E7 oncoproteins are necessary for malignant conversion.
- HPV-L1 papillomavirus major capsid protein
- VLPs virus-like particles
- primers are used to amplify specifically E6 and / or E7 DNA.
- the sequence of E6 is shown in SEQ ID NO:1, the sequence of E7 in SEQ ID NO:2.
- the specific forward primer for amplifying E6 comprises or consists of the sequence of SEQ ID NO: 3.
- the specific reverse primer for amplifying E6 comprises or consists of the sequence of SEQ ID NO: 4.
- the specific forward primer for amplifying E7 comprises or consists of the sequence of SEQ ID NO: 5.
- the specific reverse primer for amplifying E7 comprises or consists of the sequence of SEQ ID NO: 6.
- the E6 specific primer has the following sequence(s): E6: HPV16-E6 Forward GCACCAAAAGAGAACTGCAATG; HPV16- E6 Reverse GTTTGCAGCTCTGTGCATAACTG.
- the E7 specific primer has the following sequence(s): HPV16- E7 Forward CAGCTCAGAGGAGGAGGATG HPV16- E7 Reverse GTAATGGGCTCTGTCCGGT. It is understood that the sequence and composition of amplification primers are simply aligned to the sequence of interest. This is one of the methods that the person skilled in the art can easily adapt based on his expertise.
- CRISPR-associated proteins Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins) are part of a prokaryotic adaptive immune system that is represented in most archaea and many bacteria. Briefly said, this system is based on the nuclease activity of so-called (CRISPR-associated) Cas-proteins, providing efficient possibility of cutting foreign DNA or DNA fragments. Moreover, CRISPR enables incorporation of foreign fragments into CRISPR cassettes in the bacterial genome, providing recognition abilities for further infections and establishing a rudimental way of immune system.
- the CRISPR/Cas system is comprised of a small single stranded nucleotide sequence (also known as guide RNA or gRNA) and so-called Cas proteins with nuclease activity. These Cas proteins are guided by sequence complementary of the guide RNA and the target sequence of DNA to be cut. Numerous diverse Cas proteins are involved in different steps of the processing of CRISPR loci transcripts, cleavage of the target DNA or RNA, and new spacer integration. Cas proteins and their nuclease activity are used in the context of the present invention for cutting amplified DNA or DNA fragments.
- gRNA guide RNA
- Cas proteins and their nuclease activity are used in the context of the present invention for cutting amplified DNA or DNA fragments.
- the Cas protein is a type II CRISPR/Cas protein.
- CRISPR/Cas type II proteins comprise any subtype such as II-A, II-B, and II-C.
- the Cas protein is a Cas9 protein.
- the Cas protein is a type V CRISPR/Cas protein.
- CRISPR/Cas type V proteins comprise any subtype such as V-A and V-B.
- the Cas protein is Cas12.
- the Cas protein is a type VI CRISPR/Cas protein.
- CRISPR/Cas type VI proteins comprise any subtype such as VIA, VI-B, VI-C, and VI-D.
- the Cas protein is a Cas13 protein.
- Cas proteins include all Cas proteins that are capable of cutting nucleic acids, single or double-stranded, or that are having (at least partially) nuclease activity.
- the Cas protein cleaves amplified E6 DNA.
- the Cas protein cleaves amplified E7 DNA.
- the presence of a cleavage product of E6 and / or E7 DNA is detected.
- determination or “determining” the action or process of identifying the presence of cut DNA is meant.
- any method can be used for the determination of cut DNA. Determination methods are widely used in the art so far. Non-limiting examples are gel electrophoresis, bioluminescent assays, or fluorescent assays.
- multiplexed assays become relevant. Thus, in one embodiment, multiplexed assays can be used.
- fluorescent multiplex assays can be used.
- the cut DNA is detected by dipstick assays. A dipstick is one of several measurement devices, allowing the determination of present nucleotide acid fragments in a sample.
- the cleavage is determined by chromatographic separation via a lateral flow strip.
- the cleavage is determined by target-activated, non-specific single-stranded deoxyribonuclease cleavage utilizing the trans-cleavage site of Cas12 to cleave an artificial, non-target specific ssDNA, respectively labelled 5' and 3' with two different dyes to distinguish cut from uncut product.
- kits as it is used herein is to be understood as a set of articles or equipment needed for a specific purpose. Thus, a kit allows a person to easily follow the method of the invention.
- the target-activated, non-specific single-stranded deoxyribonuclease cleavage by Cas12 is detected using a kit.
- Kits as they are used in the context of the present invention, can thus comprise Cas proteins, specific guide RNA(s), nucleic acid/ssDNA, standard buffers and reagents for the detection. Reagents for the detection can also be available with an own buffer.
- the labels for the detection can, e.g., be biotin or FITC.
- the binding-partners (antibody/ligand) is invariably attached to a chromatography paper.
- biotin label binds to the first streptavidine band and will be immobilized there.
- FITC labelling of the opposite end of the product can then be detected using goat anti-FITC antibodies coupled with gold nanoparticles.
- the piece labelled with FITCs can move to the second binding site independent from biotin/streptavidine binding.
- a secondary anti-goat antibody is invariably present on the test band site. This secondary antibody in turn binds the goat anti-FITC antibody labeled with gold nanoparticles, which furthermore is bound to the FITC-coupled nucleic acid fragment.
- the cut fragment can be detected as a distinct band.
- the kit comprises Cas12 proteins, specific guide RNA(s), nucleic acid/ssDNA, standard buffers and reagents for the detection (namely the detection labels biotin and FITC). Accordingly, Cas12 recognizes a PAM (protospacer adjacent motif) and specifically cuts the targeted nucleic acid of interest, which has been amplified by using RPA. As nucleic acid markers, biotin and FITC can be used. The corresponding binding-partners are invariably attached to the chromatography paper. The uncut product is then completely found to the first biotin band.
- PAM protospacer adjacent motif
- biotin / FITC labels can be exchanged by fluorophore / quencher.
- a "quencher” as it is used herein is to be understood as a substance, which absorbs excitation energy from a fluorophore.
- the detection for cut nucleic acid takes place by Anti-FITC labelled gold-nanoparticle visualization.
- Detection means refers to a mean that is capable of detection cut nucleic acids.
- the detection means can e.g. be a chromatography paper witch invariably attached biotin or FITC. The detection means thus ensure that cut and uncut nucleic acids can be distinguished.
- the guide RNA for cutting E6 DNA comprises or consists of the sequence UAAUUUCUACUAAGUGUAGAUUGGGUCGCUCCUGUGGGUCC (SEQ ID NO: 7).
- the guide RNA for cutting E7 DNA comprises or consists of the sequence UAAUUUCUACUAAGUGUAGAUAUCCUCCUCCUCUGAGCUGU (SEQ ID NO: 8).
- the sequence and composition of the guideRNA are simply aligned to the target sequence. This is one of the methods that the person skilled in the art can easily adapt to a target sequence, based on his expertise.
- a kit comprising means for detecting the cleavage of E6 and/or E7 DNA in a body fluid.
- the kit comprises means for detecting the cleavage of E6 DNA in a body fluid.
- the kit comprises means for detecting the cleavage of E7 DNA in a body fluid.
- the cleavage is determined using the method of the first aspect of the invention, as defined above.
- the kit above can be used for the diagnosis and/or monitoring of HPV infections in a subject.
- the subject may be any animal, but is preferably a human subject.
- the third aspect also includes that the kit above can be used for the diagnosis and/or monitoring of cancer in a subject, preferably in a HPV-related cancer.
- the cancer can be selected from a non-limiting list consisting of: vulva cancer, vagina cancer, penis cancer, anus cancer, and oropharynx cancer.
- the cancer is cervix cancer.
- the cancer is oropharyngeal squamous cell carcinoma (OPSCC).
- LiBiHRD detection protocol works in four steps and can be completed in 1 hour, starting from plasma preparation.
- RPA recombinase polymerase amplification
- HPV-16 in nucleic acid extractions of specimens, two targets were chosen in the HPV-16 genome from the E6 gene and E7 gene.
- RPA amplification primers and LbCas12a CRISPR guide RNAs were designed for specific detection.
- guide sequences were selected that minimized off-targets to other HPV genomes.
- serial dilutions of HPV-16 plasmid containing E6/ E7 gene the presence of HPV-16 DNA sequence in a range between 10-1000 copies per reaction was detectable.
- Clinical specimen and plasma preparation Patient samples should be collected according to the appropriate biosafety procedures. Whole blood from patients was collected before primary treatment. Blood was drawn in commercially available Cell-Free DNA BCT collection tubes (Streck, La Vista, Iowa, USA) and centrifuged at 515 x g for 10 min at room temperature. Plasma aliquots were stored at -80°C until further analysis. The input for this protocol begins with the lysis of plasma. Collection of plasma samples with routine collection tubes is still matter of optimization.
- Step (1) treatment of plasma Triton X-100 (3051.3) (Carl Roth); PBS (Dulbecco's C-40230) (PromoCell).
- Step (2) isothermal amplification: Comercially available TwistAmp ® Basic Kit (TABAS03KIT), TwistDx Limited; Specifically designed RPA Amplification primer pairs targeting E6 and E7 gene (synthesized by Metabion). Sequences are additionally shown below.
- Target gene amplification RPA primers (5'-->3') HPV16- E6- F GCACCAAAAGAGAACTGCAATG HPV16- E6- R GTTTGCAGCTCTGTGCATAACTG HPV16- E7- F CAGCTCAGAGGAGGAGGATG HPV16- E7- R GTAATGGGCTCTGTCCGGT.
- Cas12 10x NEBuffer 2.1 and LbaCas12a (Cpf1), NEB M0653S (New England Biolabs); LbaCas12a crRNA for detecting E6 and E7 gene (synthesized by Metabion). Sequences are additionally shown below.
- Target- HPV16 LbCas12a crRNA (5'-->3') E6 gene UAAUUUCUACUAAGUGUAGAUUGGGUCGCUCCUGUGGGUCC E7 gene UAAUUUCUACUAAGUGUAGAUAUCCUCCUCCUCUGAGCUGU; Reporter DNA for lateral flow readout (Lateral-flow reporter: 5'- 6-FAM-TTATT-Bio-3', synthesized by Metabion).
- MGHD 1 HybriDetect Dipstick
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22197523.8A EP4343000A1 (fr) | 2022-09-23 | 2022-09-23 | Dosage de libihrd (analyse rapide de hpv par biopsie liquide) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22197523.8A EP4343000A1 (fr) | 2022-09-23 | 2022-09-23 | Dosage de libihrd (analyse rapide de hpv par biopsie liquide) |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4343000A1 true EP4343000A1 (fr) | 2024-03-27 |
Family
ID=84044881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22197523.8A Pending EP4343000A1 (fr) | 2022-09-23 | 2022-09-23 | Dosage de libihrd (analyse rapide de hpv par biopsie liquide) |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP4343000A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116220A2 (fr) * | 2011-02-24 | 2012-08-30 | Qiagen Gaithersburg, Inc. | Matériels et procédés de détection d'acide nucléique de hpv |
CN112111605A (zh) * | 2020-09-21 | 2020-12-22 | 中山大学附属第一医院 | 基于CRISPR-Cas12a和G四链体-血红素的HPV的检测试剂盒 |
CN112779358A (zh) * | 2021-01-27 | 2021-05-11 | 重庆威斯腾前沿生物研究院有限责任公司 | 一种dcas9介导检测HPV16型E6基因的免疫层析方法 |
CN114410838A (zh) * | 2021-12-22 | 2022-04-29 | 广州白云山拜迪生物医药有限公司 | 检测hpv16的试剂、试剂盒及应用 |
-
2022
- 2022-09-23 EP EP22197523.8A patent/EP4343000A1/fr active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116220A2 (fr) * | 2011-02-24 | 2012-08-30 | Qiagen Gaithersburg, Inc. | Matériels et procédés de détection d'acide nucléique de hpv |
CN112111605A (zh) * | 2020-09-21 | 2020-12-22 | 中山大学附属第一医院 | 基于CRISPR-Cas12a和G四链体-血红素的HPV的检测试剂盒 |
CN112779358A (zh) * | 2021-01-27 | 2021-05-11 | 重庆威斯腾前沿生物研究院有限责任公司 | 一种dcas9介导检测HPV16型E6基因的免疫层析方法 |
CN114410838A (zh) * | 2021-12-22 | 2022-04-29 | 广州白云山拜迪生物医药有限公司 | 检测hpv16的试剂、试剂盒及应用 |
Non-Patent Citations (12)
Title |
---|
BRIAN LOWE ET AL: "A hybrid-capture assay to detect HPV mRNA ratios in cervical specimens", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 179, no. 1, 13 October 2011 (2011-10-13), pages 142 - 147, XP028355346, ISSN: 0166-0934, [retrieved on 20111020], DOI: 10.1016/J.JVIROMET.2011.10.012 * |
CHEN ET AL., BIOTECHNOLOGY, 2018 |
CHEN, J. S.MA, E.HARRINGTON, L. B.DA COSTA, M.TIAN, X.PALEFSKY, J. M.DOUDNA, J. A.: "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity", SCIENCE, vol. 360, no. 6387, 2018, pages 436 - 439, XP055615609, DOI: 10.1126/science.aar6245 |
MUJAHED I MUSTAFA ET AL: "SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 59, no. 10, 1 March 2021 (2021-03-01), US, pages e00745, XP093029303, ISSN: 0095-1137, Retrieved from the Internet <URL:https://journals.asm.org/doi/epub/10.1128/JCM.00745-20> DOI: 10.1128/JCM * |
PIEPENBURG, O.WILLIAMS, C. H.STEMPLE, D. L.ARMES, N. A.: "DNA detection using recombination proteins", PLOS BIOLOGY, vol. 4, no. 7, 2006, pages e204, XP002501560, DOI: 10.1371/JOURNAL.PBIO.0040204 |
SCHEFFNER ET AL.: "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53", CELL, vol. 63, 1990, pages 1129 - 1136, XP023908049, Retrieved from the Internet <URL:https://doi.orq/10.1016/0092-8674(90)90409-8> DOI: 10.1016/0092-8674(90)90409-8 |
TSOU ET AL., TRANSL ONCOL, 2019 |
TSOU, J. H.LENG, Q.JIANG, F.: "A CRISPR test for detection of circulating nuclei acids", TRANSLATIONAL ONCOLOGY, vol. 12, no. 12, 2019, pages 1566 - 1573, XP055904233, DOI: 10.1016/j.tranon.2019.08.011 |
WAGATSUMA ET AL., J. VIROL, 1990 |
WAGATSUMA M.: "Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences", J VIROL, vol. 64, no. 2, 1990 |
ZHAO J-W: "HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 35, 2016, Retrieved from the Internet <URL:https://doi.org/10.1186/s13046-016-0454-4> |
ZHAO, J-W ET AL., BMC, 2016 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lungu et al. | Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis | |
CN108486234B (zh) | 一种crispr分型pcr的方法及其应用 | |
CN107828874B (zh) | 一种基于crispr的dna检测和分型方法及其应用 | |
Josefsson et al. | Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay | |
JP5184097B2 (ja) | HPVE6、E7mRNAアッセイ、及びその使用方法 | |
US5342930A (en) | Isolated DNA of human papillomavirus type 54(HPV54) | |
JP2007524421A (ja) | ヒトパピローマウイルスの検出 | |
CN104884638A (zh) | 用于检测人乳头瘤病毒核酸的组合物和方法 | |
US20060024686A1 (en) | Detection of human papillomaviruses | |
Wilczynski et al. | Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix | |
CN114774565A (zh) | 一种基于RPA-CRISPR-Cas12a体系可视化检测阴道毛滴虫的试剂盒及方法 | |
JP2001231587A (ja) | ヒトパピローマウイルスの短鎖ヌクレオチド配列 | |
CN106048081A (zh) | 一种hpv分型检测引物及其检测方法和应用 | |
CN109628646A (zh) | 一种基于rpa的hpv16或hpv18病毒的e6或e7核酸的检测方法 | |
Contorni et al. | Typing of human papillomavirus DNAs by restriction endonuclease mapping of the PCR products | |
CA2501030C (fr) | Methode et trousse de determination for quantitative et qualitative du papillomavirus humain | |
US20150376725A1 (en) | HPV Detection in Urine | |
EP4343000A1 (fr) | Dosage de libihrd (analyse rapide de hpv par biopsie liquide) | |
Salam et al. | General primer‐mediated polymerase chain reaction for simultaneous detection and typing of human papillomavirus DNA in laryngeal squamous cell carcinomas | |
Bartosik et al. | Advanced technologies towards improved HPV diagnostics | |
Clavel et al. | DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR. | |
EP1403384A1 (fr) | Procédé pour la détection et l'identification des HPV cutanés et amorces et sondes pour ce procédé | |
WO2020109866A1 (fr) | Association entre l'intégration de génomes viraux de vph ou de vih et la gravité et/ou le résultat clinique de troubles tels que les lésions cervicales associées au vph ou les pathologie du sida | |
CN111172328A (zh) | 用于hpv核酸分型检测的成套引物、成套探针、试剂盒和hpv核酸分型检测的方法 | |
Abdulhamit et al. | FDA-Approved Molecular Tests Used to Define Human Papillomavirus (HPV) Infections which Cause Cervix Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |